SCHEMBL254419

SCHEMBL254419

C[C@H]1CCCN1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11014798 1.00
SCHEMBL292798 1.00
SCHEMBL88667 1.00
Hydrochloric Acid SCHEMBL489347 0.97
Hydrochloric Acid SCHEMBL5763760 0.97
Ammonia Solution, Strong SCHEMBL28535747 0.97
Ammonia Solution, Strong SCHEMBL28466062 0.97
Ammonia Solution, Strong SCHEMBL1561055 0.97
SCHEMBL2442076 0.94
Hydrochloric Acid SCHEMBL21808011 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6156752-A Optically active 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC (US) 2000-12-05 US claimed
EP-0899261-A1 Optical active 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 1999-03-03 EP claimed
EP-0252720-B1 PRISTINAMYCIN PROCESS MAY & BAKER LIMITED (GB) 1991-09-18 EP claimed
US-4866172-A Pristinamycin process MAY & BAKER LIMITED (GB) 1989-09-12 US claimed
EP-0252720-A2 Pristinamycin process MAY & BAKER LIMITED (GB) 1988-01-13 EP claimed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
WO-2024138206-A1 FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF FRONTIER MEDICINES CORPORATION (US) 2024-06-27 WO disclosed
WO-2024124002-A1 COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS THIRD HARMONIC BIO, INC. (US) 2024-06-13 WO disclosed
US-20240074300-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2024-02-29 US disclosed
WO-2024036254-A2 SYNTHETIC PROCESSES AND INTERMEDIATES FOR PREPARING THERAPEUTIC AZAKETOLIDES ZIKANI THERAPEUTICS, INC. (US) 2024-02-15 WO disclosed
WO-2024015251-A1 INHIBITORS OF HPK1 AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-01-18 WO disclosed
WO-2024009191-A1 PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2024-01-11 WO disclosed
EP-1070065-A1 AZABICYCLIC 5HT1 RECEPTOR LIGANDS Pfizer Products Inc. (US) 2001-01-24 EP disclosed
US-6156752-A Optically active 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC (US) 2000-12-05 US disclosed
WO-1999052907-A1 AZABICYCLIC 5HT1 RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 1999-10-21 WO disclosed
EP-0899261-A1 Optical active 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 1999-03-03 EP disclosed
EP-0252720-B1 PRISTINAMYCIN PROCESS MAY & BAKER LIMITED (GB) 1991-09-18 EP disclosed
US-4866172-A Pristinamycin process MAY & BAKER LIMITED (GB) 1989-09-12 US disclosed
EP-0252720-A2 Pristinamycin process MAY & BAKER LIMITED (GB) 1988-01-13 EP disclosed
EP-0252720-A2 Pristinamycin process MAY & BAKER LIMITED (GB) 1988-01-13 EP disclosed